XPR1 identified as a key regulator of ovarian cancer growth through autophagy and immune evasion

 

A recent study published in Genes & Diseases reveals a novel role of XPR1 in promoting ovarian cancer growth by regulating autophagy and MHC-I expression. The research, conducted by scientists from Chongqing Medical University, identifies XPR1 as a critical factor influencing the aggressiveness of ovarian cancer through its interaction with LAMP1 and the PI3K/Akt/mTOR signaling pathway. These findings shed light on new therapeutic targets for ovarian cancer, a malignancy known for its poor prognosis and resistance to immune checkpoint inhibitors.

 

The study highlights that XPR1 expression is significantly increased in ovarian cancer tissues compared to normal ovarian tissues. This heightened expression correlates with advanced cancer stages, reduced overall survival, and lower progression-free survival. Through CRISPR-Cas9 screening, researchers identified XPR1 as a potential regulator of autophagy. Subsequent experiments confirmed that silencing XPR1 decreased ovarian cancer cell proliferation and metastasis, while overexpression led to the opposite effect, indicating its role in promoting cancer growth.

 

Further analysis revealed that XPR1 interacts with LAMP1, a key lysosomal-associated membrane protein, and regulates its expression. This interaction modulates autophagy flux, particularly during the early phase of autophagy and to some extent during the lysosomal phase. Silencing XPR1 led to increased lysosome formation and autophagy, while its overexpression suppressed these processes. The study demonstrated that XPR1 regulates autophagy through the PI3K/Akt/mTOR pathway, inhibiting autophagy flux and thereby promoting ovarian cancer cell survival.

 

In addition to autophagy regulation, the study identified a critical role of XPR1 in immune evasion. MHC-I molecules, crucial for CD8+ T cell recognition and tumor cell killing, were found to be regulated by XPR1 through autophagy. Silencing XPR1, combined with the use of chloroquine, an autophagy inhibitor, significantly enhanced the presence of MHC-I molecules on ovarian cancer cells. This combination treatment reduced tumor growth in mouse models, suggesting that targeting XPR1 alongside autophagy inhibition could improve the effectiveness of immunotherapy in ovarian cancer.

 

These findings suggest that XPR1 serves as a potential therapeutic target for ovarian cancer, especially in cases resistant to PD-1 and CTLA-4 inhibitors. Targeting XPR1, either through direct silencing or by using autophagy inhibitors, may offer a novel approach to enhance the immune response against ovarian cancer. The study provides a foundation for future research into the use of autophagy modulators in combination with immune checkpoint inhibitors to improve treatment outcomes.

 

# # # # #

Genes & Diseases publishes rigorously peer-reviewed and high quality original articles and authoritative reviews that focus on the molecular bases of human diseases. Emphasis is placed on hypothesis-driven, mechanistic studies relevant to pathogenesis and/or experimental therapeutics of human diseases. The journal has worldwide authorship, and a broad scope in basic and translational biomedical research of molecular biology, molecular genetics, and cell biology, including but not limited to cell proliferation and apoptosis, signal transduction, stem cell biology, developmental biology, gene regulation and epigenetics, cancer biology, immunity and infection, neuroscience, disease-specific animal models, gene and cell-based therapies, and regenerative medicine.

Scopus CiteScore: 8.4

Impact Factor: 9.4

 

# # # # # #

 

More information: https://www.keaipublishing.com/en/journals/genes-and-diseases/

Editorial Board: https://www.keaipublishing.com/en/journals/genes-and-diseases/editorial-board/

All issues and articles in press are available online in ScienceDirect (https://www.sciencedirect.com/journal/genes-and-diseases ).

Submissions to Genes & Disease may be made using Editorial Manager (https://www.editorialmanager.com/gendis/default.aspx ).

Print ISSN: 2352-4820

eISSN: 2352-3042

CN: 50-1221/R

Contact Us: editor@genesndiseases.com

X (formerly Twitter): @GenesNDiseases (https://x.com/GenesNDiseases )

 

# # # # # #

Reference

Hui Wang, Xiaodong Luo, Bo Yang, Furong Tang, Xingwei Jiang, Hongtao Zhu, Jianguo Hu, XPR1 promotes ovarian cancer growth and regulates MHC-I through autophagy, Genes & Diseases, Volume 12, Issue 5, 2025, 101507, https://doi.org/10.1016/j.gendis.2024.101507

 

Funding Information:

Kuanren Talents Program and Senior Medical Talents Program of the Second Affiliated Hospital of Chongqing Medical University

Senior Medical Talents Program of Chongqing for Young and Middle-aged

Chongqing Science and Technology Bureau Project CSTB2024TIAD-KPX0038

---

---